Biotech’s biggest week of 2019


Life science leaders and investors are assembling in Melbourne for biotech’s biggest week of 2019, with both AusBiotech 2019 and the Australia Biotech Invest & Partnering 2019 conference happening.

The two premier events - run by industry, for industry – are bringing over 1,400 industry leaders, investors, researchers and regulatory representatives together from 25 countries to hear over 100 speakers at the largest biotech gatherings in the Australian life science industry.

The two conferences will lift the profile of the Australian biotechnology industry, share new and ground-breaking knowledge, connect companies, and create access to greater funding sources for companies to develop world-class science into therapies, diagnostics and medical devices.

This year’s AusBiotech 2019 and the Australia Biotech Invest & Partnering 2019 events are supported by the Victorian Government as State Host Partner.

AusBiotech 2019: 30 October – 1 November

The buoyant sector will hear from world-class speakers at AusBiotech 2019, congratulate the AusBiotech and Johnson & Johnson Innovation 2019 Industry Excellence Award winners at the sold-out conference dinner, hear new research on the state of the Australian life sciences sector, attend the AusBiotech AGM to find out the result of recent Director elections, and be able to attend an early-stage investment presentation stream supporting start-ups and spin outs.

Discussions will cover global biotech trends and opportunities, policy updates and industry challenges. Topics and speakers include:

  • Gene therapy revolution, Dr Elizabeth Finkel;
  • Translating science and technology into valuable solutions for patients and consumers, Dr Tom Luby, Director, TMC Innovation Institute;
  • Millis Oration: Rebuilding kidney tissue from stem cells, Professor Melissa Little, Theme Director of Cell Biology, Murdoch Children’s Research Institute;
  • Discovery-Translation and the Valley of Death: A personal perspective, Emeritus Professor Maree Smith AC, Director, CIPDD, School of Biomedical Sciences, Faculty of Medicine, The University of Queensland;
  • Precision medicine implementation across the spectrum of health care organisations, Dr Shashikant Kulkarni, Chief Scientific Officer and Senior Vice President - Baylor Genetics and Vice Chairman for Research and Professor of Molecular and Human Genetics - Baylor College of Medicine;
  • Medicinal cannabis – new developments in Australia panel featuring: Chair: Dr Richard Hopkins, CEO, Zelda Therapeutics; Dr Stewart Washer, Executive Director, Emerald Clinics; Dr Emily Rigby, Director of Research & Compliance, Cannatrek; Ido Kanyon, CEO, AusCann Group Holdings;
  • Regenerative medicine: Advances and opportunities in Australia, featuring Australian and international success stories.

Australia Biotech Invest & Partnering 2019: 31 October

This full-day event provides investors and delegates with a “golden” opportunity to hear the latest company updates straight from the companies themselves.

Keynote speakers and 25 private and public companies spanning early to late-stage development will take centre-stage, demonstrating the potential of life science companies to an anticipated 400 delegates, including global pharmaceutical companies from around the world.

Company presentations have been scheduled in relation to their therapeutic area, ensuring investors and brokers can make the most of their time and target the therapeutics they’re most interested in. One-to-one business partnering is also available for delegates to pre-arrange business meetings with presenting companies and delegates and maximise their networking opportunities. Previous years have seen over 200 investor/company meetings scheduled.

Keynote speakers at Australian Biotech Invest & Partnering 2019 include: Ms Karimah Es Sabar, Chief Executive Officer & Partner, Quark Ventures LP, Canada: Progressive venture capital investment in health technologies; Dr Niels Emmerich, Vice President and Global Head, Search and Evaluation, AbbVie Inc., United States: New ways big pharma are engaging with the VC sector; Dr Patrik Frei, Founder and CEO, Venture Valuation, Switzerland: Valuation of biotech companies, assets and products for financing or licensing; and Giri Tenneti, Senior Manager, Issuer Services, ASX Limited: Market update.

Company spotlights include private and publicly listed companies: Sienna Cancer Diagnostics (ASX:SDX), Optiscan Imaging (ASX:OIL), Kazia Therapeutics (ASX:KZA), LBT Innovations (ASX:LBT), Carina Biotech, Microba, Imagion Biosystems (ASX:IBX), Truscreen (NSX:TRU), Apop Imaging, Immutep Limited (ASX:IMM), Zucero Therapeutics, Prescient Therapeutics (ASX:PTX), GlyTherix, Tessara Therapeutics, CK Cell Technologies, Anatara Lifesciences (ASX:ANR), Biotron Limited (ASX:BIT), Actinogen Medical (ASX:ACW), Suda Pharmaceuticals (ASX:SUD), Neuroscientific Biopharmaceuticals (ASX:NSB), Grey Innovation, Anisop Holdings, Megakaryon Corporation (Japan), Shaanxi HuiKang Bio-Tech Co. Ltd (Hong Kong), Bioinduction (United Kingdom) and Precise Light Surgical (United States).

For more information on AusBiotech 2019, click here.

For more information on Australia Biotech Invest & Partnering 2019, click here.